title: Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
authors.forename: S
authors.initials: S
authors.lastname: Giuntoli
authors.forename: E
authors.initials: E
authors.lastname: Rovida
authors.forename: V
authors.initials: V
authors.lastname: Barbetti
authors.forename: M G
authors.initials: MG
authors.lastname: Cipolleschi
authors.forename: M
authors.initials: M
authors.lastname: Olivotto
authors.forename: P
authors.initials: P
authors.lastname: Dello Sbarba
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D015687:Cell Hypoxia / Q000502:physiology; D002999:Clone Cells; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D010100:Oxygen / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D010100:Oxygen